首页 > 最新文献

Skinmed最新文献

英文 中文
Running-Associated Swollen Hands (RASH): Post Ambulatory Swollen Hands (POTASH) in a Man Who Completed a Half Marathon. 跑步相关的手肿(皮疹):跑完半程马拉松后的手肿(钾)。
Pub Date : 2024-12-31 eCollection Date: 2024-01-01
Philip R Cohen

A 64-year-old man participated in a 13.1-mile half marathon in San Diego, CA on April 23, 2023. The ambient temperature when he started the race was 54°F, which increased to 64°F on his completing the race 3 hours and 58 minutes later. Both of his hands and their digits started swelling after the first hour of running. They progressively became larger during the remainder of the race; a positive fist sign developed and the patient could not close his hands into a fist (Figure 1). Neither pruritus, swelling at any other site, nor angioedema was reported.

2023年4月23日,一名64岁的男子在加州圣地亚哥参加了13.1英里的半程马拉松比赛。当他开始比赛时,周围的温度是54华氏度,在他完成比赛3小时58分钟后,温度上升到64华氏度。在跑步的第一个小时后,他的双手和手指开始肿胀。在接下来的比赛中,它们逐渐变大;出现阳性拳头征,患者不能握拳(图1)。未见瘙痒、其他部位肿胀和血管性水肿。
{"title":"Running-Associated Swollen Hands (RASH): Post Ambulatory Swollen Hands (POTASH) in a Man Who Completed a Half Marathon.","authors":"Philip R Cohen","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>A 64-year-old man participated in a 13.1-mile half marathon in San Diego, CA on April 23, 2023. The ambient temperature when he started the race was 54°F, which increased to 64°F on his completing the race 3 hours and 58 minutes later. Both of his hands and their digits started swelling after the first hour of running. They progressively became larger during the remainder of the race; a positive fist sign developed and the patient could not close his hands into a fist (Figure 1). Neither pruritus, swelling at any other site, nor angioedema was reported.</p>","PeriodicalId":94206,"journal":{"name":"Skinmed","volume":"22 6","pages":"479-481"},"PeriodicalIF":0.0,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142924397","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hyperpigmented Scaly Lesions in the Axillae. 腋窝色素沉着的鳞状病变。
Pub Date : 2024-12-31 eCollection Date: 2024-01-01
Joel Hua-Liang Lim, Geraldine Hui-Min Ong, Joyce Siong-See Lee
{"title":"Hyperpigmented Scaly Lesions in the Axillae.","authors":"Joel Hua-Liang Lim, Geraldine Hui-Min Ong, Joyce Siong-See Lee","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":94206,"journal":{"name":"Skinmed","volume":"22 6","pages":"496-498"},"PeriodicalIF":0.0,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142924365","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Drug-Induced Subacute Cutaneous Lupus Erythematosus Associated with Fenofibrate Lipid Lowering Agent.
Pub Date : 2024-12-31 eCollection Date: 2024-01-01
Firas A Al-Qarqaz, Maha M Marji

A 53-year-old woman presented with an eruption on her face and body for 2 weeks that had developed first on the face before spreading to the trunk and extremities. There was burning with sunlight exposure. Her medical conditions included diabetes mellitus, vitamin D deficiency, and hyperlipidemia. Her treatment for the past 4 years included metformin, saxagliptin, atorvastatin, vitamin B12, vitamin D, lansoprazole, and aspirin. Because atorvastatin did not control her lipids, fenofibrate was prescribed. At 3 months, she developed photodermatitis on the sun-exposed areas of her skin and also on sun-covered areas of the chest and back. Examination showed facial erythematous scaly plaques and multiple scaly annular erythematous plaques on her trunk and extremities (Figure 1). Methylprednisolone aceponate ointment, pimecrolimus ointment 0.1%, and sunblock were prescribed. Her facial eruption was only minimally lessened, while the dermatitis worsened on the trunk, arms, and legs.

{"title":"Drug-Induced Subacute Cutaneous Lupus Erythematosus Associated with Fenofibrate Lipid Lowering Agent.","authors":"Firas A Al-Qarqaz, Maha M Marji","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>A 53-year-old woman presented with an eruption on her face and body for 2 weeks that had developed first on the face before spreading to the trunk and extremities. There was burning with sunlight exposure. Her medical conditions included diabetes mellitus, vitamin D deficiency, and hyperlipidemia. Her treatment for the past 4 years included metformin, saxagliptin, atorvastatin, vitamin B12, vitamin D, lansoprazole, and aspirin. Because atorvastatin did not control her lipids, fenofibrate was prescribed. At 3 months, she developed photodermatitis on the sun-exposed areas of her skin and also on sun-covered areas of the chest and back. Examination showed facial erythematous scaly plaques and multiple scaly annular erythematous plaques on her trunk and extremities (Figure 1). Methylprednisolone aceponate ointment, pimecrolimus ointment 0.1%, and sunblock were prescribed. Her facial eruption was only minimally lessened, while the dermatitis worsened on the trunk, arms, and legs.</p>","PeriodicalId":94206,"journal":{"name":"Skinmed","volume":"22 6","pages":"472-474"},"PeriodicalIF":0.0,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143054758","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Secrets of the Stratum Corneum I: Parakeratosis or Porokeratosis? 角质层的秘密I:角化不全还是角化不全?
Pub Date : 2024-12-31 eCollection Date: 2024-01-01
Sara Behbahani, Steven Skula, Marcus L Elias, Shreya Patel, Radhika Shah, José D Espinal-Mariotte, Robert A Schwarz, W Clark Lambert
{"title":"Secrets of the Stratum Corneum I: Parakeratosis or Porokeratosis?","authors":"Sara Behbahani, Steven Skula, Marcus L Elias, Shreya Patel, Radhika Shah, José D Espinal-Mariotte, Robert A Schwarz, W Clark Lambert","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":94206,"journal":{"name":"Skinmed","volume":"22 6","pages":"454-457"},"PeriodicalIF":0.0,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142924399","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Combination of Multi-Acid Superficial Peel and Hyaluronic Acid Boosting: A Novel Prejuvenation Strategy. 多酸浅层去皮与增强透明质酸的结合:一种新的防幼化策略。
Pub Date : 2024-12-31 eCollection Date: 2024-01-01
Nicoletta Banzola, Francesca Negosanti

Normal human life expectancy has increased; hence, growing interest in the field of skin quality is observed. Peels are common medical devices that stimulate new skin growth and improve texture. Injectable hyaluronic acid (HA)-based products act by replacing fragmented collagen. HA skin boosting is a new technique that is able to reduce aging indicators. The aim of this study was to evaluate the efficacy and safety of a multi-acid superficial peel combined with an HA skin booster to improve quality of the skin. We conducted a prospective study with patients presenting hyperpigmentation, skin dryness, loss of elasticity, or fine lines. The participants were required to apply either peel or booster treatment during an attack phase and during the followed maintenance phase. Subjective and objective evaluations were performed to assess clinical outcomes (i.e., skin hydration, firmness, and brightness). A total of 16 subjects participated in the study. We observed a higher satisfaction at the end of the treatment, compared to the baseline, for each of the three skin qualities (P < 0.0001). Similarly, analysis of physicians' global assessment scores demonstrated that physicians detected higher scores at the end of the study, compared to the baseline (P < 0.0001). Our study demonstrated the synergistic effect of a multi-acid superficial peel combined with HA skin boosting to improve skin appearance.

人类的正常预期寿命增加了;因此,人们对皮肤质量领域的兴趣日益浓厚。换肤是一种常见的医疗器械,可以刺激新皮肤生长,改善皮肤质地。注射透明质酸(HA)为基础的产品的作用是取代碎片胶原蛋白。透明质酸提肤是一项能够减少衰老指标的新技术。本研究的目的是评估多酸浅表去皮联合透明质酸皮肤增强剂改善皮肤质量的有效性和安全性。我们对出现色素沉着、皮肤干燥、失去弹性或细纹的患者进行了一项前瞻性研究。参与者被要求在攻击阶段和随后的维护阶段应用剥离或加强治疗。进行主观和客观评价来评估临床结果(即皮肤水合度、紧致度和亮度)。共有16名受试者参与了这项研究。我们观察到在治疗结束时,与基线相比,三种皮肤质量的满意度更高(P < 0.0001)。同样,对医生总体评估分数的分析表明,医生在研究结束时检测到的分数高于基线(P < 0.0001)。我们的研究证明了多酸浅表去皮与透明质酸皮肤增强相结合的协同作用,可以改善皮肤外观。
{"title":"Combination of Multi-Acid Superficial Peel and Hyaluronic Acid Boosting: A Novel Prejuvenation Strategy.","authors":"Nicoletta Banzola, Francesca Negosanti","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Normal human life expectancy has increased; hence, growing interest in the field of skin quality is observed. Peels are common medical devices that stimulate new skin growth and improve texture. Injectable hyaluronic acid (HA)-based products act by replacing fragmented collagen. HA skin boosting is a new technique that is able to reduce aging indicators. The aim of this study was to evaluate the efficacy and safety of a multi-acid superficial peel combined with an HA skin booster to improve quality of the skin. We conducted a prospective study with patients presenting hyperpigmentation, skin dryness, loss of elasticity, or fine lines. The participants were required to apply either peel or booster treatment during an attack phase and during the followed maintenance phase. Subjective and objective evaluations were performed to assess clinical outcomes (i.e., skin hydration, firmness, and brightness). A total of 16 subjects participated in the study. We observed a higher satisfaction at the end of the treatment, compared to the baseline, for each of the three skin qualities (<i>P</i> < 0.0001). Similarly, analysis of physicians' global assessment scores demonstrated that physicians detected higher scores at the end of the study, compared to the baseline (<i>P</i> < 0.0001). Our study demonstrated the synergistic effect of a multi-acid superficial peel combined with HA skin boosting to improve skin appearance.</p>","PeriodicalId":94206,"journal":{"name":"Skinmed","volume":"22 6","pages":"428-432"},"PeriodicalIF":0.0,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142924278","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Racial/Ethnic Disparities in Cutaneous T-cell Lymphoma: A Clinical Review. 皮肤t细胞淋巴瘤的种族差异:临床综述
Pub Date : 2024-12-31 eCollection Date: 2024-01-01
Preeti Kakani, Jeremy Davis

A relative paucity of published papers is observed regarding racial and ethnic disparities in cutaneous T cell lymphoma (CTCL). Although CTCL is a rare condition, the poor outcomes associated with this condition underscore the need to understand and address any existing care inequities. Recently, a growing body of literature has attempted to identify racial disparities in CTCL in terms of the overall survival, stage at presentation, time to initiate treatment, and complication rate. Some progress has been made in understanding the underlying causes of such disparities, with some proposing the biologic and genetic differences between Caucasian and black patients, others proposing that environmental exposure to chemicals, such as benzene, may predispose certain populations to the disease, and still others suggesting that other factors related to socioeconomic status, such as insurance type, may play a role. We review what is known about racial and ethnic differences in clinical presentations, existing health disparities, key hypotheses regarding drivers of these trends, and actionable strategies to address these disparities.

关于皮肤T细胞淋巴瘤(CTCL)的种族和民族差异,发表的论文相对较少。尽管CTCL是一种罕见的疾病,但与这种疾病相关的不良结果强调了了解和解决任何现有护理不平等的必要性。最近,越来越多的文献试图从总体生存期、发病阶段、开始治疗时间和并发症发生率等方面确定CTCL的种族差异。在了解这种差异的根本原因方面取得了一些进展,一些人提出白种人和黑人患者之间的生物和遗传差异,另一些人提出接触化学品(如苯)的环境可能使某些人群易患这种疾病,还有一些人认为与社会经济地位有关的其他因素,如保险类型,可能起作用。我们回顾了临床表现中已知的种族和民族差异,现有的健康差异,关于这些趋势驱动因素的关键假设,以及解决这些差异的可行策略。
{"title":"Racial/Ethnic Disparities in Cutaneous T-cell Lymphoma: A Clinical Review.","authors":"Preeti Kakani, Jeremy Davis","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>A relative paucity of published papers is observed regarding racial and ethnic disparities in cutaneous T cell lymphoma (CTCL). Although CTCL is a rare condition, the poor outcomes associated with this condition underscore the need to understand and address any existing care inequities. Recently, a growing body of literature has attempted to identify racial disparities in CTCL in terms of the overall survival, stage at presentation, time to initiate treatment, and complication rate. Some progress has been made in understanding the underlying causes of such disparities, with some proposing the biologic and genetic differences between Caucasian and black patients, others proposing that environmental exposure to chemicals, such as benzene, may predispose certain populations to the disease, and still others suggesting that other factors related to socioeconomic status, such as insurance type, may play a role. We review what is known about racial and ethnic differences in clinical presentations, existing health disparities, key hypotheses regarding drivers of these trends, and actionable strategies to address these disparities.</p>","PeriodicalId":94206,"journal":{"name":"Skinmed","volume":"22 6","pages":"422-426"},"PeriodicalIF":0.0,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142924386","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Retreatment with Brentuximab Vedotin for CD30+ Cutaneous T-cell Lymphoma and Lymphomatoid Papulosis. 布伦妥昔单抗维多汀治疗CD30+皮肤t细胞淋巴瘤和类淋巴瘤丘疹病。
Pub Date : 2024-12-31 eCollection Date: 2024-01-01
David M Weiner, Daniel J Lewis
{"title":"Retreatment with Brentuximab Vedotin for CD30+ Cutaneous T-cell Lymphoma and Lymphomatoid Papulosis.","authors":"David M Weiner, Daniel J Lewis","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":94206,"journal":{"name":"Skinmed","volume":"22 6","pages":"489-490"},"PeriodicalIF":0.0,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142924390","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Medicare Part D Prescription Claims for Tofacitinib and Baricitinib, 2017-2021. Tofacitinib和Baricitinib的医疗保险D部分处方索赔,2017-2021。
Pub Date : 2024-12-31 eCollection Date: 2024-01-01
Lina Alhanshali, Jerry Shapiro, Kristen Lo Sicco
{"title":"Medicare Part D Prescription Claims for Tofacitinib and Baricitinib, 2017-2021.","authors":"Lina Alhanshali, Jerry Shapiro, Kristen Lo Sicco","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":94206,"journal":{"name":"Skinmed","volume":"22 6","pages":"486-489"},"PeriodicalIF":0.0,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142924371","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Sweet Syndrome-Like Disorder Induced by the Oxford-AstraZeneca® SARS-CoV-2 Vaccine. 牛津-阿斯利康®SARS-CoV-2疫苗诱导的甜蜜综合征样疾病
Pub Date : 2024-12-31 eCollection Date: 2024-01-01
Bruna O Schoenardie, Jéssica P Damke, Lia D P Dantas, Renan R Bonamigo
{"title":"Sweet Syndrome-Like Disorder Induced by the Oxford-AstraZeneca<sup>®</sup> SARS-CoV-2 Vaccine.","authors":"Bruna O Schoenardie, Jéssica P Damke, Lia D P Dantas, Renan R Bonamigo","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":94206,"journal":{"name":"Skinmed","volume":"22 6","pages":"494-496"},"PeriodicalIF":0.0,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142924400","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Lockdown Lessons from Dermatology Consultations during the COVID-19 Pandemic in a Tertiary Care Center. COVID-19大流行期间三级医疗中心皮肤科会诊的封锁经验。
Pub Date : 2024-12-31 eCollection Date: 2024-01-01
Niti Khunger, Sushruta Kathuria
{"title":"Lockdown Lessons from Dermatology Consultations during the COVID-19 Pandemic in a Tertiary Care Center.","authors":"Niti Khunger, Sushruta Kathuria","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":94206,"journal":{"name":"Skinmed","volume":"22 6","pages":"490-494"},"PeriodicalIF":0.0,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142924370","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Skinmed
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1